Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Lidia Altomare"'
Publikováno v:
Clinical Management Issues, Vol 4, Iss 2S, Pp 21-25 (2015)
We report a case of a 42-year-old woman with t(9;22) positive chronic myeloid leukemia (CML) who developed a sub-optimal response to therapy with imatinib mesylate due to M351T mutation and low plasma level of imatinib. Dose increase of imatinib resu
Externí odkaz:
https://doaj.org/article/6bafb979a1664177a0c23c7d08bcdca9
Autor:
Marianna Pezzella, Valentino Manzo, Sergio Ferrari, Elisa Capone, Michele Spiniello, Massimo Napolitano, Lia Allegorico, Giorgia Teresa Maniscalco, Sara Mariotto, Lidia Altomare, Gennaro Alfieri, Giovanna Servillo, Rosaria Renna, Angelo Ranieri
Publikováno v:
Neurological Sciences. 42:1531-1534
Anti-myelin oligodendrocyte glycoprotein antibody-associated disorders (MOGAD) are new emerging diseases with heterogeneous course, treatment, response, and prognosis. We herein present 2 cases with antibodies to MOG, one with a cerebellar/brainstem
Publikováno v:
Clinical Management Issues; Vol 4, No 2S (2010); 21-25
Clinical Management Issues, Vol 4, Iss 2S, Pp 21-25 (2015)
Clinical Management Issues, Vol 4, Iss 2S, Pp 21-25 (2015)
We report a case of a 42-year-old woman with t(9;22) positive chronic myeloid leukemia (CML) who developed a sub-optimal response to therapy with imatinib mesylate due to M351T mutation and low plasma level of imatinib. Dose increase of imatinib resu
Autor:
Guiseppe Cimino, Sergio Mecarocci, Mariella D'Andrea, Lidia Altomare, Elisabetta Cerchiara, Andrea Mengarelli, Maria Laura Dessanti, Valeria Tomarchio, Guiseppe Avvisati, Maria Cristina Tirindelli, Odoardo Maria Olimpieri, Natalia Cenfra, Francesco Marchesi, Maria Concetta Petti, Angela Rago
The clinical outcome of elderly (≥75years) patients with aggressive B-cell non-Hodgkin lymphoma (B-NHL) is not firmly established because few studies have specifically addressed this issue. In addition, the usefulness of a comprehensive geriatric a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba971cc0a0b4dd5bad4dbfe385e49b52
http://hdl.handle.net/11573/557499
http://hdl.handle.net/11573/557499
Autor:
Maria Giuseppina Cefalo, Stefano Ceccarelli, Lorenzo Moretta, Gianpiero Conflitti, Giuseppina Li Pira, Valentina Bertaina, Barbarella Lucarelli, Perla Filippini, Sergio Rutella, Tiziana Corsetti, Alice Bertaina, Elia Girolami, Franco Locatelli, Lidia Altomare, Letizia Pomponia Brescia
Publikováno v:
Journal of Translational Medicine
Background HLA-haploidentical hematopoietic stem cell transplantation (HSCT) is suitable for patients lacking related or unrelated HLA-matched donors. Herein, we investigated whether plerixafor (MZ), as an adjunct to G-CSF, facilitated the collection